<?xml version="1.0" encoding="UTF-8"?>
<p>At present, some 40 antiviral drugs have been formally licensed for use in humans, mostly for treatment of human immunodeficiency virus, hepatitis B virus, and herpesvirus infections. The number of antiviral drugs that have been licensed for use in treating highly-pathogenic RNA virus infections is very limited; the current list of approved drugs includes anti-influenza medications, M2 channel inhibitors (amantadine and rimantadine), and neuramidase inhibitors (oseltamivir and zanaminir). Ribavirin is licensed for the treatment of respiratory syncytial virus and hepatitis C virus infections [
 <xref ref-type="bibr" rid="B12">12</xref>,
 <xref ref-type="bibr" rid="B13">13</xref>]. Pleconaril, an antiviral drug developed in 1996 for treatment of diseases associated with picornavirus infections, can be used in treatments against enterovirus and rhinovirus infections [
 <xref ref-type="bibr" rid="B14">14</xref>]. However, the treatment of this drug was extremely limited and reported to pleconaril-resistant viruses [
 <xref ref-type="bibr" rid="B15">15</xref>,
 <xref ref-type="bibr" rid="B16">16</xref>].
</p>
